tazarotene · Mayne Pharma · NDA 202428
Fabior
Earliest generic entry, as listed
24 Feb 2030
Blocked by patent: US 10568859, US 10688071, US 8808716.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10568859 | product, use U-2760 | 24 Feb 2030 |
| US 10688071 | product, use U-2760 | 24 Feb 2030 |
| US 8808716 | product | 24 Feb 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202428 · 001 · RLD | aerosol, foam, topical | 0.1% | 24 Feb 2030 |